Each week, Pharmaceutical Technology’s journalists analyse data on patent filings and grants that illustrate innovation trends in our sector. These patent signals show where the leading companies are focusing their research and development investment, and why. We uncover key innovation areas in the sector and the themes that drive them.  

This new, thematic patents coverage is powered by our underlying Disruptor data which tracks all major deals, patents, company filings, hiring patterns and social media buzz across our sectors.  

This week, we take a look at geographic and therapy trends when it comes to patent filings by entities in the pharmaceutical space over Q2 2023. In that time period, China was a clear leader in terms of the number of patent grants. This was then followed by the US, Japan and South Korea.

Geographic distribution of patent filings in the pharmaceutical space in Q2. Source: GlobalData.

Patents allow biotech and pharmaceutical companies to stand out in the competitive therapeutic research and development landscape. Most patents filed in Q2 were related to inflammation-related research, followed closely by diabetes and Alzheimer’s disease. This is in line with recent trends with drugs in those therapy areas, especially diabetes and obesity, emerging as major revenue streams for companies.

GlobalData is the parent company of Pharmaceutical Technology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.